Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
20 participants
INTERVENTIONAL
2016-11-30
2020-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
NCT06329908
Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
NCT02419170
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
NCT05235607
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
NCT05317325
Personalized DC Vaccine for Postoperative Cancer
NCT04147078
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cell_therapy
tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
DC vaccine
subcutaneous administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DC vaccine
subcutaneous administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* failed in previous standard chemotherapy and targeted therapy
* anticipated life time \> 3month
* Karnofsky performance status 0-1
* rehabilitate from previous therapy
* adequate organ functions
Exclusion Criteria
* tumor emergency
* abnormal coagulation condition
* contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
* concomitant tumors
* immunological co-morbidities
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhen-Yu Ding
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhen-Yu Ding, Prof
Role: PRINCIPAL_INVESTIGATOR
Sichuan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China West Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKLB1608
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.